Work

NEJM at ESMO — Overall Survival with Pembrolizumab in Early-Stage Triple- Negative Breast Cancer

Year: 2024

Type: editorial

Source: New England Journal of Medicine

DOI: 10.1056/nejme2411492

Authors: Eric J. Rubin, Oladapo O. Yeku, Stephen Morrissey

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4402552134

Cites:

Cited by: 2

Related to: 10